Strategic partnerships Recent termination of the standby equity agreement with Yorkville Equity Partners and ongoing collaboration with academic institutions like the University at Buffalo suggest Trinity Biotech is open to strategic partnerships and co-development opportunities. Approach: explore joint research, embedded diagnostics, and co-marketing arrangements with complementary tech or data center healthcare ecosystems.

AI and data center momentum Launch of Trinovium targeting the AI data center liquid cooling market indicates a pivot toward high-growth, tech-forward applications. Sales opportunities exist in providing rapid deployment diagnostic tools or monitoring solutions for AI infrastructure environments, leveraging Trinity’s diagnostic expertise for uptime and reliability.

North America expansion Appointment to lead North America commercial operations signals a push into the U.S. market. Leverage this expansion to propose standardized, scalable diagnostic workflows for clinics and hospitals, plus region-specific regulatory-compliant kits and support packages.

Clinical biomarkers focus Partnership with University at Buffalo to commercialize biomarkers for Sjögren's Syndrome showcases a focus on niche, high-value diagnostics. Opportunities exist in co-marketing, distribution partnerships, and funding-backed pilots for specialized biomarker panels and companion diagnostics.

Integrated glucose monitoring Rollout of Innovative Glucose Monitoring System and strong HbA1c platform differentiation position Trinity Biotech in chronic disease management. Target healthcare providers with bundled diagnostics and monitoring hardware/software integrations to streamline patient testing workflows and data capture.